Renal and urinary proteomics: Current applications and challenges

During the past few years, proteomics has been extensively applied to various fields of medicine including nephrology. Current applications of renal and urinary proteomics are to better understand renal physiology, to explore the complexity of disease mechanisms, and to identify novel biomarkers and new therapeutic targets. This review provides some examples and perspectives of how proteomics can be applied to nephrology and how experimental data can be linked to physiology, functional significance and clinical applications. In some instances, proteomic analysis can be utilized to generate a new hypothesis from a set of candidates that are obtained from expression studies. The new hypothesis can then be addressed rapidly by conventional molecular biology methods, as demonstrated by identification of an altered renal elastin‐elastase system in diabetic nephropathy and alterations in the renal kallikrein‐kallistatin pathway in hypoxia‐induced hypertension. The strengths and limitations of proteomics in renal research are summarized. Optimization of analytical protocols is required to overcome current limitations. Applications of proteomics to nephrology will then be more fruitful and successful.

[1]  J. Celis,et al.  Towards a comprehensive database of proteins from the urine of patients with bladder cancer. , 1996, The Journal of urology.

[2]  M. Knowles,et al.  Urological malignancies and the proteomic‐genomic interface , 1999, Electrophoresis.

[3]  D. Hochstrasser,et al.  Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase , 2001, Proteomics.

[4]  V. Somers,et al.  Impairment of Endothelium-Dependent Vasodilation of Resistance Vessels in Patients With Obstructive Sleep Apnea , 2000, Circulation.

[5]  D. Chan,et al.  Characterization of Renal Allograft Rejection by Urinary Proteomic Analysis , 2003, Annals of surgery.

[6]  L. Nelin,et al.  Role of Endothelin in Intermittent Hypoxia-Induced Hypertension , 2001, Hypertension.

[7]  Jian Cai,et al.  Differential expression of proteins in renal cortex and medulla: a proteomic approach. , 2002, Kidney international.

[8]  W. Pierce,et al.  Sodium loading changes urinary protein excretion: a proteomic analysis. , 2003, American journal of physiology. Renal physiology.

[9]  J. Reilly,et al.  Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation , 1996, British journal of haematology.

[10]  M. Rastaldi,et al.  Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. , 2002, Kidney international.

[11]  R. Palmiter,et al.  Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. , 1988, The American journal of pathology.

[12]  A. Desmoulière,et al.  Cellular Retinol-Binding Protein-1 Expression and Modulation during In Vivo and In Vitro Myofibroblastic Differentiation of Rat Hepatic Stellate Cells and Portal Fibroblasts , 2002, Laboratory Investigation.

[13]  C. Guilleminault,et al.  Vascular reactivity in obstructive sleep apnea syndrome. , 2000, American journal of respiratory and critical care medicine.

[14]  Anders Blomberg,et al.  Interlaboratory reproducibility of yeast protein patterns analyzed by immobilized pH gradient two‐dimensional gel electrophoresis , 1995, Electrophoresis.

[15]  B. Seliger,et al.  Targeting of tumor associated antigens in renal cell carcinoma using proteome‐based analysis and their clinical significance , 2002, Proteomics.

[16]  C. Scharf,et al.  Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. , 2001, European journal of biochemistry.

[17]  E. Fletcher,et al.  Blood pressure response to chronic episodic hypoxia: role of the sympathetic nervous system. , 1997, Journal of applied physiology.

[18]  R. Walther,et al.  Human agmatinase is diminished in the clear cell type of renal cell carcinoma , 2004, International journal of cancer.

[19]  Frank A Witzmann,et al.  Cutting-edge technology. II. Proteomics: core technologies and applications in physiology. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[20]  O. Jensen,et al.  Optimized preparation of urine samples for two-dimensional electrophoresis and initial application to patient samples. , 2002, Clinical biochemistry.

[21]  M. Raida,et al.  Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry. , 1997, Journal of chromatography. A.

[22]  B. Seliger,et al.  Identification of markers for the selection of patients undergoing renal cell carcinoma‐specific immunotherapy , 2003, Proteomics.

[23]  U. Plessmann,et al.  Amino acid sequence characterization of mammalian vimentin, the mesenchymal intermediate filament protein , 1983, FEBS letters.

[24]  Rosamonde E Banks,et al.  Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma , 2003, Proteomics.

[25]  R. Mejia,et al.  Database for renal collecting duct regulatory and transporter proteins. , 2003, Physiological genomics.

[26]  P. Nickerson,et al.  Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. , 2004, Kidney international.

[27]  G. Striker,et al.  Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. , 1995, Endocrinology.

[28]  T. Marshall,et al.  Two‐dimensional electrophoresis of human urinary proteins following concentration by dye precipitation , 1996, Electrophoresis.

[29]  B. Seliger,et al.  Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. , 2003, Biochimica et biophysica acta.

[30]  L. Chao,et al.  Kallistatin is a potent new vasodilator. , 1997, The Journal of clinical investigation.

[31]  M. Katori,et al.  Role of the Renal Kallikrein-Kinin System in the Development of Salt-Sensitive Hypertension , 2001, Biological chemistry.

[32]  B. Seliger,et al.  Heat shock protein expression and anti‐heat shock protein reactivity in renal cell carcinoma , 2002, Proteomics.

[33]  R. Wait,et al.  Proteins of rat serum, urine, and cerebrospinal fluid: VI. Further protein identifications and interstrain comparison , 2001, Electrophoresis.

[34]  Thorsten Kaiser,et al.  Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. , 2003, Journal of chromatography. A.

[35]  M. Takata,et al.  Focal segmental glomerulosclerosis associated with acromegaly. , 2001, Clinical nephrology.

[36]  F. Witzmann,et al.  Differential expression of cytosolic proteins in the rat kidney cortex and medulla: Preliminary proteomics , 1998, Electrophoresis.

[37]  K. Zatloukal,et al.  Identification of tumor antigens in renal cell carcinoma by serological proteome analysis , 2001, Proteomics.

[38]  P. Nickerson,et al.  Proteomic-based detection of urine proteins associated with acute renal allograft rejection. , 2004, Journal of the American Society of Nephrology : JASN.

[39]  L. Chao,et al.  Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein. , 1990, The Biochemical journal.

[40]  J. Celis,et al.  Bladder squamous cell carcinoma biomarkers derived from proteomics , 2000, Electrophoresis.

[41]  B. Rovin,et al.  Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. , 2004, Journal of the American Society of Nephrology : JASN.

[42]  R. Wahl,et al.  Towards defining the urinary proteome using liquid chromatography‐tandem mass spectrometry I.Profiling an unfractionated tryptic digest , 2001, Proteomics.

[43]  N. Wahab,et al.  J Am Soc Nephrol 14: 1358–1373, 2003 Extracellular Matrix Metabolism in Diabetic Nephropathy , 2022 .

[44]  Rembert Pieper,et al.  Characterization of the human urinary proteome: A method for high‐resolution display of urinary proteins on two‐dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots , 2004, Proteomics.

[45]  A. Hishida,et al.  Focal segmental glomerulosclerosis in a case of panhypopituitarism: a possible role of growth hormone treatment. , 2002, Clinical nephrology.

[46]  N. Saeki,et al.  Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: report of a rare clinical case. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  L. Chao,et al.  Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. , 2000, Kidney international.

[48]  Jian Cai,et al.  Proteomic Analysis Reveals Alterations in the Renal Kallikrein Pathway during Hypoxia-Induced Hypertension* , 2002, The Journal of Biological Chemistry.

[49]  Visith Thongboonkerd,et al.  Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. , 2002, Kidney international.

[50]  D. Hochstrasser,et al.  Renal cell carcinoma and normal kidney protein expression , 1997, Electrophoresis.

[51]  P. Selby,et al.  Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. , 2003, Cancer research.

[52]  M. Knowles,et al.  Proteomic changes in renal cancer and co‐ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect , 2003, Proteomics.